Transcriptomics

Dataset Information

0

Expression Data from transNOAH breast cancer trial


ABSTRACT: These data can be used for evaluation of the clinical utility of the research-based PAM50 subtype predictor in predicting pathological complete response (pCR) and event-free survival (EFS) in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial. The NeOAdjuvant Herceptin [NOAH] trial demonstrated that trastuzumab significantly improves pCR rates and 3-year event-free survival (EFS) in combination with neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with HER2+ breast cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE50948 | GEO | 2014/01/21

SECONDARY ACCESSION(S): PRJNA219444

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-04-01 | GSE109710 | GEO
2019-05-08 | GSE130787 | GEO
2019-05-08 | GSE130786 | GEO
2011-05-11 | E-GEOD-25065 | biostudies-arrayexpress
2011-05-11 | E-GEOD-25055 | biostudies-arrayexpress
2012-12-11 | E-GEOD-42822 | biostudies-arrayexpress
2012-12-11 | GSE42822 | GEO
2016-03-31 | E-GEOD-62327 | biostudies-arrayexpress
2021-08-24 | GSE181574 | GEO
2012-05-11 | E-GEOD-37946 | biostudies-arrayexpress